Introduction
============

Cirrhosis is diffuse liver damage induced by various chronic hepatitis diseases for a long time or under the influence of repeated actions. With the aggravation of the disease course, portal hypertension will occur in patients leading to esophageal and gastric varices ([@b1-etm-0-0-8106]--[@b4-etm-0-0-8106]). Esophageal and gastric varices are the common causes of gastrointestinal hemorrhage. Esophagogastric varices rupture hemorrhage is one of the serious clinical complications of cirrhosis due to large amount of hemorrhage, dangerous onset and high mortality rate ([@b5-etm-0-0-8106]--[@b7-etm-0-0-8106]).

Clinically, TIPS technology is widely used to treat esophageal and gastric variceal bleeding caused by portal hypertension. TIPS is a minimally invasive method to establish stents to artificially distribute blood, which reduces portal pressure to prevent esophageal and gastric variceal bleeding ([@b8-etm-0-0-8106]--[@b10-etm-0-0-8106]). However, the restenosis rate of blood shunts and the incidence rate of hepatic encephalopathy are high after TIPS is used, and the mid- and long-term curative effects of patients after treatment are poor, which are defects of TIPS technology. With the appearance of covered stent, evidence-based medicine shows that the stenosis rate of blood shunt after covered stent is significantly improved, but there are still some adverse prognosis problems ([@b11-etm-0-0-8106],[@b12-etm-0-0-8106]). Subsequently, FID of the United States recommended using Viatorr stent for TIPS ([@b13-etm-0-0-8106]), but the stent price is higher and the usage rate is lower. Therefore, clinical workers simulated Viatorr stent and applied double stents in TIPS ([@b14-etm-0-0-8106]--[@b16-etm-0-0-8106]). As the clinical efficacy of double stent simulated Viatorr stent in TIPS, is not very clear we studied and compared the clinical efficacy of single covered stent and double stents in TIPS for the treatment of cirrhotic esophageal and gastric variceal bleeding, providing certain reference for clinical treatment of cirrhotic esophageal and gastric variceal bleeding under pressure.

Patients and methods
====================

### Collection of specimens

Altogether 124 patients with liver cirrhosis and esophageal and gastric varices bleeding admitted to the First People\'s Hospital of Neijiang (Neijiang, China) from February 2012 to April 2016 were selected as research objects and divided into groups A and B. Among them, 65 patients with simple covered stent were selected as group A, including 47 males and 18 females, with an average age of 43.5±2.3 years. Another 59 patients treated with double stent technique simulating Viatorr method were taken as group B, including 38 males and 21 females, with an average age of 42.8±2.8 years.

This study was approved by the Medical Ethics Committee of the First People\'s Hospital of Neijiang. Patients who participated in this research had complete clinical data. Signed informed consents were obtained from the patients or the guardians.

### Inclusion and exclusion criteria

Inclusion criteria: Patients were diagnosed as cirrhosis and with complete clinical data; with poor therapeutic effect through drugs and endoscopy and high risk of surgical operation; without cerebrovascular diseases and malignant tumor diseases; who can be followed up and with Budd-Chiari syndrome.

Exclusion criteria: Patients with coagulation dysfunction, severe infectious diseases, combined with other liver and kidney diseases, hepatic vein occlusion, or polycystic liver disease.

### Treatment methods

Firstly, according to the patient\'s imaging data, the positional relationship between hepatic vein and portal vein was determined before operation to ensure the safety of the puncture route. The patient was required to take the supine position, the operation site was disinfected and anesthetized. The position relationship between hepatic vein and portal vein was determined again after preoperative preparation to ensure the accuracy of the puncture. The puncture position was the right internal jugular vein of the patient, and the portal vein pressure was measured after the puncture was confirmed to be successful and the position was appropriate. The varicose vein was embolized by springs according to the direct portal angiography result. After the puncture was completed, a balloon catheter was introduced to expand the intrahepatic puncture under fluoroscopy, and a stent was selected according to the incision of the balloon. The covered stent was required not to block the ipsilateral portal vein blood flow in human liver. Double stents were first implanted with bare stents to connect the portal vein, and then implanted with film or bare stents. The stents were released in a precise location. After completion, the walking and expansion of stents in the shunt were observed again through direct portal venography. After confirmation, the catheter could be removed, and then the puncture opening was bandaged.

### Postoperative treatment and follow-up

After the operation, the puncture point of the patient was pressed to stop bleeding, blood routine and liver function of the patient were tested, and anticoagulants were administered orally every day. All patients were followed up by telephone and outpatient review for two years after surgery, every three months in the first year of follow-up and every six months in the second year of follow-up. The follow-up ended in April 2018.

### Observation indicators

Main observation indicators: The clinical efficacy of two groups of patients after different stent operations was observed ([Table I](#tI-etm-0-0-8106){ref-type="table"}) as well as the immune function of patients after operation.

Secondary observation indicators: The changes of portal vein pressure before and after operation in the two groups, and the changes of esophageal and gastric varices in the two groups were observed ([Table II](#tII-etm-0-0-8106){ref-type="table"}). The survival conditions of the groups two years after operation were recorded.

### Statistical analysis

SPSS 19.0 software (SPSS Inc.) was used in this study for statistical analysis. GraphPad Prism 7 software was used to visualize the data in this study. The enumeration data was expressed by rate (%) and detected by Chi-square test, while the measurement data was expressed by mean ± standard deviation (mean ± SD). Independent sample t-test was used to compare the two groups, and K-M survival curve was used to analyze the recurrence of patients within two years. Statistical significance is indicated by P\<0.05.

Results
=======

### General clinical data of groups A and B

There was no difference in age, sex, BMI (kg/m^2^), liver function Child-Pugh classification, etiology of liver cirrhosis, preoperative portal vein width, residence, smoking, alcoholism and other general clinical baseline data between groups A and B (P\>0.05) ([Table III](#tIII-etm-0-0-8106){ref-type="table"}).

### Evaluation of curative effect of two groups of patients

Comparing the curative effect evaluation of the two groups of patients, it was found that the total effective rate of group A was 83.08%, and of B was 93.22%. The total effective rate of patients in group B was higher than that in group A (P\>0.05) ([Table IV](#tIV-etm-0-0-8106){ref-type="table"}).

The changes of portal vein pressure before and after operation in the two groups. Preoperative portal pressure in group A was 31.64±6.21 and postoperative portal pressure was 20.67±5.34. Preoperative portal pressure in group B was 30.12±6.07 and postoperative portal pressure was 17.29±5.16. There was no difference in portal vein pressure between the two groups (P\>0.05). The portal vein pressure in group B was significantly lower than that in group A (P\<0.05) ([Fig. 1](#f1-etm-0-0-8106){ref-type="fig"}).

### Comparison of changes of esophagogastric varices between two groups

The degree of esophageal and gastric varices after operation in both groups was significantly improved compared with that before operation. The disappearance rate and overall effective rate of varicose veins in group B were better than those in group A (P\>0.05) ([Table V](#tV-etm-0-0-8106){ref-type="table"}).

### Changes of immune function in two groups of patients

The changes of CD3^+^, CD4^+^ and CD4^+^/CD8^+^ before treatment, 3 and 7 days after treatment in the two groups were observed. Compared with the changes of CD3^+^, CD4^+^ and CD4^+^/CD8^+^ 3 and 7 days after treatment in group A, there was no statistical difference (P\>0.05). After treatment for 3 days in group B, CD3^+^, CD4^+^ and CD4^+^/CD8^+^ were higher than those in group A. After 7 days of treatment, the decrease rate of CD3^+^, CD4^+^ and CD4^+^/CD8^+^ in group B was higher than that in group A (P\>0.05) ([Table VI](#tVI-etm-0-0-8106){ref-type="table"}).

### Two-year survival of two groups of patients

Statistics on the survival of the two groups of patients were made for two years. Altogether 124 patients or their families were followed up, with 0 patients lost to follow-up. Within two years, 12 patients died, 112 survived, with a survival rate of 90.32%. Eight patients died in group A, 57 survived, and the survival rate was 87.69%. Four patients died in group B, 55 survived, and the survival rate was 93.22%. The two-year survival rate of the patients in group B was higher than that in group A, with no statistical significance (P=0.298) ([Fig. 2](#f2-etm-0-0-8106){ref-type="fig"}).

Discussion
==========

Esophagogastric varices are common complications of liver cirrhosis. Liver cirrhosis is pathologically defined as liver, which leads to metabolic liver failure and portal hypertension ([@b17-etm-0-0-8106],[@b18-etm-0-0-8106]). Portal hypertension is the most common complication of liver cirrhosis, and esophageal varices are portal mesangium of patients with liver cirrhosis with portal hypertension ([@b19-etm-0-0-8106]). Every year, a certain proportion of cirrhotic patients develop esophageal varices, which is the main cause of death for cirrhotic patients ([@b20-etm-0-0-8106]). TIPS is the main treatment method for esophageal varices rupture and hemorrhage. In recent years, the appearance of covered stent and double-stent simulated Viatorr methods have further optimized TIPS treatment ([@b21-etm-0-0-8106]). Therefore, this study investigated the efficacy of the two stent methods in TIPS.

We compared the clinical efficacy of covered stent and double stent in TIPS treatment of liver cirrhosis patients with esophageal and gastric varices bleeding. The results showed that the therapeutic efficacy of patients with double stent was higher than that of patients with single covered stent. In the study of Sommer *et al* ([@b22-etm-0-0-8106]), the hemodynamics, patency rate and complications of Viatorr stent in TIPS treatment were higher than those of bare metal stent, and the clinical success rate was better than those of bare metal stent, which was similar to our results. Furthermore, we compared the therapeutic effects of single covered stent and double stents (i.e. simulated Viatorr stent method) in TIPS. The single covered stent was improved on the basis of bare metal stents and was more effective than bare metal stents in preventing variceal rebleeding. This view has also been confirmed in the study conducted by Bucsics *et al* ([@b23-etm-0-0-8106]). However, the appearance of Viator stents in the United States provides a new concept in TIPS therapy. In our study, we also show that the simulated Viatorr double stent method has better curative effect, which further supports our research results. In addition, we also observed that the portal vein pressure of patients applying the two stent methods is lower than that of patients applying single covered stent. In the study of the Zhao *et al* ([@b24-etm-0-0-8106]), the portal vein pressure of patients after Viatorr stent treatment was reduced, which was similar to our results. We speculate that the double stent can effectively improve the patency of the shunt and reduce the pressure of the shunt to prevent varicose veins. Double stents are used to simulate Viatorr stents with the same effect for TIPS therapy, further supporting our research results. Moreover, we observed that the varicose degree of patients after both stent operations was improved, and the varicose disappearance rate in patients using double stents was higher. Then, we observed the immune function of patients after surgery. Compared with patients with single covered stent, the immune function of patients with double covered stent increased three days after surgery, and the rate of recovery was higher than that of patients with single covered stent. According to the recovery of patients\' immune function, we consider that the double covered stent method can effectively reduce bleeding symptoms and complications. In the study of Ferral *et al* ([@b15-etm-0-0-8106]), Viatorr stent, which is the double covered stent we simulated, has excellent shunt unblocking rate and better therapeutic effect. After two years of follow-up investigation, the results showed that the survival rate of patients with double stents is higher than that of patients with single covered stents, which suggests that the application of double stents in TIPS may be beneficial to the survival of patients.

This study initially proved that the clinical effect of double stents in TIPS treatment of liver cirrhosis esophageal and gastric fundus varices hemorrhage is better, but this study still has certain limitations as we did not study the complications of patients and did not make a good prognosis. The number of samples and the research time need to be increased in the follow-up studies.

In conclusion, double stents are more effective in TIPS in the treatment of liver cirrhosis with esophageal and gastric variceal bleeding, promoting the rapid recovery of immune function, and are worthy of clinical application and promotion.
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###### 

Evaluation criteria for efficacy.

  Grade                Criteria
  -------------------- ---------------------------------------------------------------------------------------
  Markedly effective   Hemostasis within 8 h, no black stool and haematemesis within 2 weeks.
  Effective            Hemostasis within 24 h, no black stool and haematemesis within 2 weeks.
  Ineffective          Active bleeding was still present within 24 h and recurrence occurred within 2 weeks.

###### 

Grading criteria of esophagogastric varices.

  Grade       Form of esophageal varicosis (F)       Red color (RC)
  ----------- -------------------------------------- ----------------
  Mild (G1)   Straight or slightly circuitous (F1)   No
  Moderate    Straight or slightly circuitous (F1)   Yes
  (G2)        Snake roundabout uplift (F2)           No
  Severe      Snake roundabout uplift (F2)           Yes
  (G3)        Beads, nodules, tumors (F3)            No or yes

###### 

General clinical data of groups A and B \[n (%)\].

  Factor                                A (n=65)     B (n=59)     t/χ^2^ value   P-value
  ------------------------------------- ------------ ------------ -------------- ---------
  Sex                                                             0.896          0.344
    Male                                47 (72.31)   38 (64.41)                  
    Female                              18 (27.69)   21 (35.59)                  
  Age (years)                           43.5±2.3     42.8±2.8     1.527          0.129
  BMI (kg/m^2^)                         24.35±1.72   23.87±1.69   1.565          0.120
  Liver function Child-Pugh grading                               0.505          0.477
    Grade A                             30 (46.15)   31 (52.54)                  
    Grade B                             35 (53.85)   28 (47.46)                  
  Etiology of liver Cirrhosis                                     1.110          0.775
    Posthepatitic B Cirrhosis           32 (49.23)   26 (44.07)                  
    Posthepatitic C Cirrhosis           5 (7.69)     3 (5.08)                    
    Alcoholic cirrhosis                 7 (10.77)    6 (10.17)                   
    Others                              21 (32.31)   24 (40.68)                  
  Preoperative portal vein width (cm)   1.27±0.14    1.34±0.21    2.202          0.030
  Residence                                                       1.343          0.247
    Urban                               44 (67.69)   34 (57.63)                  
    Rural                               21 (32.31)   25 (42.37)                  
  Smoking history                                                 0.016          0.898
    Yes                                 29 (44.62)   27 (45.76)                  
    No                                  36 (55.38)   32 (54.24)                  
  Drinking history                                                0.482          0.488
    Yes                                 36 (55.38)   29 (49.15)                  
    No                                  29 (44.62)   30 (50.85)                  

###### 

Efficacy evaluation of two groups of patients \[n(%)\].

                       A (n=65)     B (n=59)     χ^2^ value   P-value
  -------------------- ------------ ------------ ------------ ---------
  Markedly effective   25 (38.46)   32 (54.24)   3.099        0.078
  Effective            29 (44.62)   23 (38.98)   0.403        0.536
  Ineffective          11 (16.92)   4 (6.78)     2.993        0.084
  Total effective      54 (83.08)   55 (93.22)   2.993        0.084

###### 

Degree of esophagogastric varices in two groups of patients after treatment.

  Degree of varicose   A (n=65)     B (n=59)     χ^2^ value   P-value
  -------------------- ------------ ------------ ------------ ---------
  G1                   26 (40.00)   25 (42.37)   0.072        0.789
  G2                   16 (24.62)   14 (23.73)   0.013        0.908
  G3                   12 (18.46)   5 (8.47)     2.607        0.106
  Disappearance        11 (16.92)   15 (25.42)   1.349        0.246

###### 

Changes of CD3^+^ CD4^+^ and CD4^+^/CD8^+^ before, after 3 and 7 days of treatment in the two groups of patients.

             CD3^+^       CD4^+^       CD4^+^/CD8^+^                                                                  
  ---------- ------------ ------------ --------------- ------------ ------------ ------------ ----------- ----------- -----------
  A (n=65)   50.35±6.23   53.47±4.75   52.32±4.43      43.12±5.07   46.87±5.11   43.47±4.06   0.83±0.34   1.25±0.39   0.92±0.36
  B (n=59)   50.87±6.45   55.23±5.47   51.07±3.23      42.69±4.58   48.32±4.72   42.13±3.89   0.76±0.28   1.36±0.42   0.82±0.31
  t value    0.649        1.917        1.780           0.494        1.636        1.872        1.244       1.512       1.649
  P-value    0.456        0.057        0.078           0.622        0.104        0.064        0.216       0.133       0.102

[^1]: Contributed equally
